NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

InMed Pharmaceuticals Inc. (INM) Stock Analysis

InMed Pharmaceuticals Inc. (INM) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

INM

$1.38

+$0.05 (+3.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare INM with… →

INM Key Statistics

As of Sep 4, 2026
Trading
Open
$1.34
Previous Close
$1.33
Day's Range
1.33–1.40
52-Week Range
0.58–2.50
Volume
7.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.98
Valuation
Market Cap
$7.37M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.49
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.47
Financials (FY)
Revenue (FY)
$4.94M+7.50%
Net Income (FY)
−$8.16M
Profit marginThe share of revenue left as profit after all costs and taxes.
−172.17%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
5.34M
1-Year Return
−33.97%
Dividend and dates
Earnings Date
September 23, 2026estimated
Avg Volume
937.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

INM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+30.19%
2025−77.64%
2024−43.03%
2023−79.41%
2022−93.83%
2021−60.18%
2020−44.61%
2019−29.41%
2018−76.06%
2017+526.47%
2016 (partial year)+157.58%

As of September 4, 2026.

INM Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$4.94M−$8.16M−165.1%
2024$4.60M−$7.68M−166.9%
2023$4.14M−$7.95M−192.2%
2022$1.09M−$18.60M−1707.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.94M$1.71M−$7.92M−$8.16M−165.1%
2024$4.60M$1.10M−$8.13M−$7.68M−166.9%
2023$4.14M$1.40M−$8.38M−$7.95M−192.2%
2022$1.09M$543.55K−$13.79M−$18.60M−1707.3%

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

INM Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricINMDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.492.3035% below
Profit margin−172.17%−3.14%169.0 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

InMed Pharmaceuticals Inc. (INM) carries a market capitalisation of $7.37M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 13.

Over the past 52 weeks the price has ranged from $0.58 to $2.50. The most recent close on file for INM is $1.38, dated September 4, 2026. That is +$0.05 (+3.76%) against the previous close. The latest close sits 140% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.94M. Against the prior fiscal year total of $4.60M, that is a change of +7.50%. The same year closed with a net loss of $8.16M. The reported profit margin is −172.17%. That is 169 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −1.47.

Across the 4 fiscal years on file, revenue moves from $1.09M in 2022 to $4.94M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 1.49. On price-to-sales that is 35.08% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −33.97%. Across 10 years the annualized return works out at −48.27%. Beta against the wider market is reported at 0.98. Annualized volatility over the trailing 10 years is 137.56%.

Growth & Income

The record shows no dividend for INM.

The strongest complete calendar year on file is 2017 at +526.47%; the weakest is 2022 at −93.83%. Of the 9 complete calendar years on file, 1 finished higher. So far in 2026 the price is +30.19%.

Peer Comparison

InMed Pharmaceuticals Inc. (INM) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
InMed Pharmaceuticals Inc. INM $7.37M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. InMed Pharmaceuticals Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Visit website →